+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Drug Delivery Devices Market (2021-2026) by device type, route of administration, application, end-user, vehicle outlook, Geography, Competitive Analysis and the Impact of COVID-19 with Ansoff Analysis

  • ID: 5317140
  • Report
  • April 2021
  • Region: Global
  • 182 Pages
  • Infogence Global Research
until Jan 31st 2022


  • 3M
  • AstraZeneca PLC
  • Biocorp Production.
  • Generex Biotechnology
  • Koninklijke Philips N.V.
  • Novartis AG
The Global Drug Delivery Devices Market is estimated to be USD 22.2 Bn in 2021 and is expected to reach USD 28.7 Bn by 2026, growing at a CAGR of 5.3%.

Market Dynamics

Key factors, such as the rising geriatric population coupled with increasing chronic ailments such as diabetes, cancer, etc have led to a growth in drug delivery devices. The surge in non-communicable diseases has also led to the demand for non-invasive drug delivery methods. Additionally, the growth of biologics is significantly contributing to the drug delivery device market.

However, factors such as drug recalls and biocompatibility issues with increased side effects are likely to restrain the market growth of drug delivery devices. Moreover, the time taken for approval of novel drugs is also likely to hamper the growth of drug delivery devices due to the subsequent delay in deliveries.

Market Segmentation

The Global Drug Delivery Devices Market is segmented further based on device type, route of administration, application, end-user, vehicle outlook, and Geography.

By Device Type, the market is classified as smart pills, inhalers, drug-eluting stents, safety syringes, implantable drug delivery devices, transdermal patches, and others. Amongst all, the smart pills segment is estimated to hold the highest market share.

By Route of Administration, the market is classified as Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical, and Others. Amongst all, the oral route of administration is estimated to hold the highest market share.

By Application, the market is classified as Oncology, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, and Others. Amongst all, the diabetes segment is estimated to hold the highest market share during the forecast period.

By End User, the market is classified as Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Home Care Settings, and Others. Amongst all, the hospital segment holds the highest market share.

By Vehicle Outlook, the market is classified as a hydrogel, micelle, dendrimer, nanoparticle, liposomes, scaffold, niosomes, and mesoporous materials. Amongst all, the nanoparticle segment is estimated to hold the highest market share.

By Geography, North America is projected to lead the market.

Recent Developments
1. 3M has re-launched its drug delivery systems through Kindeva, a global contract manufacturing/ development firm focusing on drug delivery projects. This is the newly formed independent entity formed along with Altair post the sales of the drug delivery systems units to Altair Capital Partners for USD 650 Mn. - 4th May 2020
2. Bayer is venturing into an agreement with Exscientia for the identification and optimization of novel lead structures for potential drug candidates in treating cardiovascular and oncological diseases. - 22nd January 2020

Company Profiles

Some of the companies covered in this report are 3M Company, AstraZeneca PLC, Becton, Dickinson, Boehringer Ingelheim group, GlaxoSmithKline plc, Insulet Corporation, Medtronic Plc, Sulzer Ltd. and West Pharmaceuticals Services, Inc.

Competitive Quadrant

The report includes a Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Drug Delivery Devices Market.
  • The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes in-depth market analysis using Porter’s 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
  • The report also contains the competitive analysis using Competitive Quadrant, the analyst's proprietary competitive positioning tool.

Report Highlights:
  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Note: Product cover images may vary from those shown


  • 3M
  • AstraZeneca PLC
  • Biocorp Production.
  • Generex Biotechnology
  • Koninklijke Philips N.V.
  • Novartis AG
1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders

2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study

3 Executive Summary

4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers Growing geriatric population and rising ailments Increasing demand for non-invasive drug-delivery methods Growth in the biologics markets
4.2.2 Restraints High cases of drug recalls Biocompatibility issues High time taken for approval of novel drugs
4.2.3 Opportunities Growth in Nanotechnology and technological advancements Growing R&D investments
4.2.4 Challenges Inefficiencies in delivering poorly soluble drugs Lack of trained professionals to administer the drugs
4.3 Trends

5 Market Analysis
5.1 Porter’s Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis

6 Global Drug Delivery Device Market, By Device Type
6.1 Introduction
6.2 Smart Pills
6.3 Inhalers
6.4 Drug Eluting Stents
6.5 Safety Syringes
6.6 Implantable Drug Delivery Device
6.7 Transdermal Patches
6.8 Others

7 Global Drug Delivery Devices Market, By Route of Administration
7.1 Introduction
7.2 Oral
7.3 Inhalation
7.4 Transdermal
7.5 Injectable
7.6 Ocular
7.7 Nasal
7.8 Topical
7.9 Others

8 Global Drug Delivery Devices Market, By Application
8.1 Introduction
8.2 Oncology
8.3 Infectious Diseases
8.4 Respiratory Diseases
8.5 Diabetes
8.6 Cardiovascular Diseases
8.7 Autoimmune Diseases
8.8 Central Nervous System Disorders
8.9 Others

9 Global Drug Delivery Devices Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Diagnostic Centers
9.4 Ambulatory Surgery Centers/Clinics
9.5 Home Care Settings
9.6 Others

10 Global Drug Delivery Devices Market, By Vehicles Outlook
10.1 Introduction
10.2 Hydrogel
10.2.1 Oncology
10.2.2 Infectious Diseases
10.2.3 Respiratory Diseases
10.2.4 Diabetes
10.2.5 Cardiovascular Diseases
10.2.6 Autoimmune Diseases
10.2.7 Central Nervous System Disorders
10.2.8 Others
10.3 Micelle
10.3.1 Oncology
10.3.2 Infectious Diseases
10.3.3 Respiratory Diseases
10.3.4 Diabetes
10.3.5 Cardiovascular Diseases
10.3.6 Autoimmune Diseases
10.3.7 Central Nervous System Disorders
10.3.8 Others
10.4 Dendrimer
10.4.1 Oncology
10.4.2 Infectious Diseases
10.4.3 Respiratory Diseases
10.4.4 Diabetes
10.4.5 Cardiovascular Diseases
10.4.6 Autoimmune Diseases
10.4.7 Central Nervous System Disorders
10.4.8 Others
10.5 Nanoparticle
10.5.1 Oncology
10.5.2 Infectious Diseases
10.5.3 Respiratory Diseases
10.5.4 Diabetes
10.5.5 Cardiovascular Diseases
10.5.6 Autoimmune Diseases
10.5.7 Central Nervous System Disorders
10.5.8 Others
10.6 Liposome
10.6.1 Oncology
10.6.2 Infectious Diseases
10.6.3 Respiratory Diseases
10.6.4 Diabetes
10.6.5 Cardiovascular Diseases
10.6.6 Autoimmune Diseases
10.6.7 Central Nervous System Disorders
10.6.8 Others
10.7 Scaffold
10.7.1 Oncology
10.7.2 Infectious Diseases
10.7.3 Respiratory Diseases
10.7.4 Diabetes
10.7.5 Cardiovascular Diseases
10.7.6 Autoimmune Diseases
10.7.7 Central Nervous System Disorders
10.7.8 Others
10.8 Mesoporous Material
10.8.1 Oncology
10.8.2 Infectious Diseases
10.8.3 Respiratory Diseases
10.8.4 Diabetes
10.8.5 Cardiovascular Diseases
10.8.6 Autoimmune Diseases
10.8.7 Central Nervous System Disorders
10.8.8 Others
10.9 Niosomes
10.9.1 Oncology
10.9.2 Infectious Diseases
10.9.3 Respiratory Diseases
10.9.4 Diabetes
10.9.5 Cardiovascular Diseases
10.9.6 Autoimmune Diseases
10.9.7 Central Nervous System Disorders
10.9.8 Others

11 Global Drug Delivery Devices Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 South America
11.3.1 Brazil
11.3.2 Argentina
11.4 Europe
11.4.1 UK
11.4.2 France
11.4.3 Germany
11.4.4 Italy
11.4.5 Spain
11.4.6 Rest of Europe
11.5 Asia-Pacific
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4 Indonesia
11.5.5 Malaysia
11.5.6 South Korea
11.5.7 Australia
11.5.8 Russia
11.5.9 Rest of APAC
11.6 Rest of the World
11.6.1 Qatar
11.6.2 Saudi Arabia
11.6.3 South Africa
11.6.4 United Arab Emirates
11.6.5 Latin America

12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
12.3 Competitive Scenario
12.3.1 Mergers & Acquisitions
12.3.2 Agreement, Collaborations, & Partnerships
12.3.3 New Product Launches & Enhancements
12.3.4 Investments & Funding

13 Company Profiles
13.1 Pfizer, Inc
13.2 Johnson & Johnson Services, Inc
13.3 F. Hoffmann-La Roche, Ltd
13.4 Novartis AG
13.5 3M
13.6 Bayer AG
13.7 uniQure N.V.
13.8 Shenzhen (SiBiono) GeneTech Co. Ltd (Hubei Tongji Benda Ebei Pharmaceuticals)
13.9 Antares Pharma, Inc
13.10 GlaxoSmithKline plc
13.11 AstraZeneca PLC
13.12 Becton Dickinson
13.13 Boehringer Ingelheim group
13.14 Consort Medical plc (Recipharm Group)
13.15 Insulet Corporation
13.16 Medtronic Plc
13.17 Sulzer Ltd.
13.18 West Pharmaceuticals Services, Inc
13.19 Generex Biotechnology
13.20 Panacea Pharmaceuticals Inc.
13.21 Aptar Pharma
13.22 Koninklijke Philips N.V.
13.23 Nemera
13.24 Biocorp Production.
13.25 Eli Lilly and Co.

14 Appendix
14.1 Questionnaire
Note: Product cover images may vary from those shown
  • Pfizer, Inc
  • Johnson & Johnson Services, Inc
  • F. Hoffmann-La Roche, Ltd
  • Novartis AG
  • 3M
  • Bayer AG
  • uniQure N.V.
  • Shenzhen (SiBiono) GeneTech Co. Ltd (Hubei Tongji Benda Ebei Pharmaceuticals)
  • Antares Pharma, Inc
  • GlaxoSmithKline plc
  • AstraZeneca PLC
  • Becton Dickinson
  • Boehringer Ingelheim group
  • Consort Medical plc (Recipharm Group)
  • Insulet Corporation
  • Medtronic Plc
  • Sulzer Ltd.
  • West Pharmaceuticals Services, Inc
  • Generex Biotechnology
  • Panacea Pharmaceuticals Inc.
  • Aptar Pharma
  • Koninklijke Philips N.V.
  • Nemera
  • Biocorp Production.
  • Eli Lilly and Co.
Note: Product cover images may vary from those shown